This is a working overview of anxiolytic, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-28 and is reviewed periodically as new material appears.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.
Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.
Enzymatic stability motivates the extra three residues at the carboxyl end. Native tuftsin is cleaved quickly by circulating aminopeptidases and carboxypeptidases, which limits its duration of action and its usefulness as a tool compound. Extending the chain with proline-rich segments is a common design tactic because proline constrains the backbone and slows proteolysis. The same Pro-Gly-Pro motif appears in other Russian-developed peptides of the era. Whether the full seven-residue chain is required for activity, or whether it acts mainly as a prodrug releasing tuftsin, remains unresolved.
Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.
Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Tuftsin analogue with a C-terminal Pro-Gly-Pro tail |
| Amino acid sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Abbreviated TKPRPGP in most catalogues |
| Molecular mass | About 752 Da | Value for the free peptide |
| Solubility | Freely soluble in water | Aqueous solutions are kept cold and used promptly |
| Typical storage | -20 °C, dry, protected from light | Applies to the lyophilised powder before reconstitution |
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.
The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.
Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
== External links == Media related to Parathyroid hormone at Wikimedia Commons Parathyroid hormone: analyte monograph - the Association for Clinical Biochemistry and Laboratory Medicine Overview of all the structural information available in the PDB for UniProt: P01270 (Parathyroid hormone) at the PDBe-KB.
=== Description === Eflornithine is a "suicide inhibitor," irreversibly binding to ornithine decarboxylase (ODC) and preventing the natural substrate ornithine from accessing the active site (Figure 1). Within the active site of ODC, eflornithine undergoes decarboxylation with the aid of cofactor pyridoxal 5'-phosphate (PLP). Because of its additional difluoromethyl group in comparison to ornithine, eflornithine is able to bind to a neighboring Cys-360 residue, permanently remaining fixated within the active site.
the first technological developments were a thinner-gauge device-shell, and a filler gel of low-cohesion silicone, which improved the functionality and the verisimilitude (size, appearance, and texture) of the silicone-gel breast implant. Yet, in clinical practice, second-generation breast implants proved fragile and saw greater instances of shell rupture, and of filler leakage ("silicone-gel bleed") through the intact device shell. The consequent, increased incidence-rates of medical complications (e.g. capsular contracture) precipitated faulty-product, class action-lawsuits, by the U.S. government, against the Dow Corning Corporation, and other manufacturers of breast prostheses. the second technological development was a polyurethane foam coating for the shell of the breast implant; the coating reduced the incidence of capsular contracture, by causing an inflammatory reaction that impeded the formation of a capsule of fibrous collagen tissue around the breast implant. Nevertheless, despite that prophylactic measure, the medical use of polyurethane-coated breast implants was briefly discontinued, because of the potential health-risk posed by 2,4-toluenediamine (TDA), a carcinogenic by-product of the chemical breakdown of the polyurethane foam coating of the breast implant proven to cause liver and skin cancers in animal-model studies. After reviewing the medical data, the U.S.
Stargirl and her team were briefly introduced in the Arrowverse crossover "Crisis on Infinite Earths" in January 2020, through archive footage from "The Justice Society" episode. Stargirl is set on a new Earth-2, created during the crossover. Stargirl from the pre-Crisis Earth-1 had previously appeared in three episodes of season two of Legends of Tomorrow, portrayed by Sarah Grey, between October 2016 and February 2017. Regarding any proper crossovers with the Arrowverse, Johns and Bassinger were keen on the idea. Johns said that "right now the main concern is making sure that this show is great, that these characters are great, that they have their own stories and they get the proper screen time and the proper episodes to develop on their own. So hopefully in the future we can do something fun, but the first season is all about making sure that Stargirl is the best show it can possibly be". Bassinger added that there had already been preliminary discussion about crossing over with The Flash, and she was hopeful to be able to crossover with Melissa Benoist on Supergirl. John Wesley Shipp reprised his role as an alternate version of Jay Garrick from The Flash. Johns said Shipp's appearance helped connect "our universe directly with the other shows, and also shows that were part of a grander universe. It opens up the door to opportunities for us to eventually interact with those Arrowverse characters, and that was important".
Sources: en.wikipedia.org
Paul Berg, a Nobel laureate in chemistry, wrote to the Senate that "Quackery will always prey on the gullible and uninformed, but we should not provide it with cover from the NIH," and called the office "an embarrassment to serious scientists". Allen Bromley, then-president of the American Physical Society, similarly wrote to Congress that the OAM had "emerged as an undiscriminating advocate of unconventional medicine. It has bestowed the considerable prestige of the NIH on a variety of highly dubious practices, some of which clearly violate basic laws of physics". Leon Jaroff, writing for The New York Times in 1997, described the OAM as "Tom Harkin's folly". In 1995, Wayne Jonas, a promoter of homeopathy and political ally of Harkin, became the director of the OAM, and continued in that role until 1999. In 1997, the NCCAM budget was increased from $12 million to $20 million annually. From 1990 to 1997, use of alternative medicine in the US increased by 25%, with a corresponding 50% increase in expenditures. The OAM drew increasing criticism from eminent members of the scientific community with letters to the Senate Appropriations Committee when discussion of renewal of funding OAM came up. In 1998, the President of the North Carolina Medical Association publicly called for shutting down the OAM. In 1998, NIH director and Nobel laureate Harold Varmus came into conflict with Harkin by pushing to have more NIH control of alternative medicine research. The NIH Director placed the OAM under stricter scientific NIH control.
In these cases, usually the half-life of interest in radiometric dating is the longest one in the chain, which is the rate-limiting factor in the ultimate transformation of the radioactive nuclide into its stable daughter. Isotopic systems that have been exploited for radiometric dating have half-lives ranging from only about 10 years (e.g., tritium) to over 100 billion years (e.g., samarium-147). For most radioactive nuclides, the half-life depends solely on nuclear properties and is essentially constant. This is known because decay constants measured by different techniques give consistent values within analytical errors and the ages of the same materials are consistent from one method to another. It is not affected by external factors such as temperature, pressure, chemical environment, or presence of a magnetic or electric field. The only exceptions are nuclides that decay by the process of electron capture, such as beryllium-7, strontium-85, and zirconium-89, whose decay rate may be affected by local electron density. For all other nuclides, the proportion of the original nuclide to its decay products changes in a predictable way as the original nuclide decays over time. This predictability allows the relative abundances of related nuclides to be used as a clock to measure the time from the incorporation of the original nuclides into a material to the present.
== Distribution == UCN III is widely distributed throughout the brain and is present in many bodily tissues—including the skin, gastrointestinal tract (GI tract), pancreatic beta cells, kidneys, heart, endocrine system, and brain. The medial amygdala (MeA), rostral perifornical area of the hypothalamus, bed nucleus of the stria terminalis (BNST), superior paraolivary nucleus, nucleus parabrachialis, and premammillary nucleus are the primary locations where UCN III is expressed. Expression of UCN III occurs late in the differentiation process of beta cells, where it is necessary for complete insulin secretion triggered by glucose and incretin, and is shown in mature beta cells in both mice and humans. Beta cells use the ATP-sensitive potassium channel (KATP channel) to facilitate the glucose-dependent release of UCN III. This is corroborated by the expression of PC1/3, Nkx6.1, and Pdx1 in hESC-derived UCN III + beta cells. But human UCN III is not specific to the beta cell lineage; rather, it is a generic marker for both the alpha and beta cell lineages, as seen by its expression in primary and hESC-derived alpha cells. A universal marker of alpha and beta cell development in humans is Ucn III. After triggering the receptors in the cerebral endothelial cells, UCN III crosses the blood–brain barrier, as demonstrated by a transneuronal tracer injection into the ventral pre-mammillary nucleus of the rat brain.
Sources: en.wikipedia.org
Selank is a seven-amino-acid peptide built from the tuftsin sequence plus a Pro-Gly-Pro tail. It is produced by chemical synthesis rather than extracted from a natural source. The free peptide is usually supplied as a lyophilised powder or in an aqueous formulation.
Tuftsin is a natural tetrapeptide derived from the Fc portion of immunoglobulin G. Selank retains that tetrapeptide at its N-terminus and adds three residues to improve resistance to enzymatic breakdown. The relationship is structural, and the two molecules are not interchangeable in experimental work.
It holds a product registration in Russia for intranasal use as an anxiolytic. Registrations of that kind are not automatically accepted by regulators elsewhere. In most other countries it is treated as an unapproved substance or a research material.
Selank is a synthetic peptide made of seven amino acids. It is modeled on tuftsin, a natural tetrapeptide, with an added three-residue tail. It is not a small-molecule drug.